IN2014DN00202A - - Google Patents

Info

Publication number
IN2014DN00202A
IN2014DN00202A IN202DEN2014A IN2014DN00202A IN 2014DN00202 A IN2014DN00202 A IN 2014DN00202A IN 202DEN2014 A IN202DEN2014 A IN 202DEN2014A IN 2014DN00202 A IN2014DN00202 A IN 2014DN00202A
Authority
IN
India
Prior art keywords
recombinant
antibody
expression vector
provides
bacterial cell
Prior art date
Application number
Inventor
Mark Ellis
David Paul Humphreys
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Publication of IN2014DN00202A publication Critical patent/IN2014DN00202A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

The present invention provides a recombinant gram negative bacterial cell comprising and expression vector comprising a recombinant polynucleotide encoding DsbC and one or more polynucleotides encoding an antibody or an antigen binding fragment thereof specifically binding to CD154.
IN202DEN2014 2011-07-13 2012-07-13 IN2014DN00202A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11173880 2011-07-13
PCT/EP2012/002945 WO2013007388A1 (en) 2011-07-13 2012-07-13 Bacterial host strain expressing recombinant dsbc

Publications (1)

Publication Number Publication Date
IN2014DN00202A true IN2014DN00202A (en) 2015-06-05

Family

ID=46545736

Family Applications (1)

Application Number Title Priority Date Filing Date
IN202DEN2014 IN2014DN00202A (en) 2011-07-13 2012-07-13

Country Status (27)

Country Link
US (2) US9725516B2 (en)
EP (2) EP3339325A1 (en)
JP (3) JP6431370B2 (en)
KR (1) KR102023786B1 (en)
CN (1) CN103649124B (en)
AU (1) AU2012283388B2 (en)
BR (1) BR112013032871B1 (en)
CA (1) CA2841824C (en)
CY (1) CY1119985T1 (en)
DK (1) DK2731973T3 (en)
EA (1) EA031449B1 (en)
ES (1) ES2659155T3 (en)
HR (1) HRP20180226T1 (en)
HU (1) HUE035674T2 (en)
IL (1) IL229947B (en)
IN (1) IN2014DN00202A (en)
LT (1) LT2731973T (en)
ME (1) ME02957B (en)
MX (1) MX348738B (en)
NO (1) NO2731973T3 (en)
PL (1) PL2731973T3 (en)
PT (1) PT2731973T (en)
RS (1) RS56926B1 (en)
SG (1) SG10201807560XA (en)
SI (1) SI2731973T1 (en)
SM (1) SMT201800068T1 (en)
WO (1) WO2013007388A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2125894T (en) * 2007-03-22 2019-03-25 Biogen Ma Inc. Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof
BR112012006670B8 (en) 2009-09-24 2022-03-03 Ucb Pharma Sa Recombinant gram-negative bacterial cell, and method for producing a recombinant protein
GB201000591D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201000590D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
GB201000587D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201012599D0 (en) 2010-07-27 2010-09-08 Ucb Pharma Sa Process for purifying proteins
KR102023786B1 (en) * 2011-07-13 2019-09-20 유씨비 파마, 에스.에이. Bacterial host strain expressing recombinant dsbc
GB201208367D0 (en) * 2012-05-14 2012-06-27 Ucb Pharma Sa Biological product
GB201223276D0 (en) * 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
CN107108692B (en) 2014-12-22 2021-01-29 Ucb生物制药私人有限公司 Protein production
KR101810778B1 (en) * 2015-06-23 2017-12-20 서울대학교산학협력단 CD154 binding polypeptide and its use
RU2018128784A (en) 2016-01-27 2020-02-27 МЕДИММЬЮН, ЭлЭлСи Methods for producing antibodies with a given glycosylation profile
CN111954683A (en) 2018-04-05 2020-11-17 生物辐射Abd瑟罗泰克有限公司 Display systems for proteins of interest
EP3877407A1 (en) 2018-11-05 2021-09-15 F. Hoffmann-La Roche AG Methods of producing two chain proteins in prokaryotic host cells
CN109371049A (en) * 2018-11-14 2019-02-22 天津大学 Application of molecular chaperone in promoting the formation of monoclonal antibody and/or increasing the expression of monoclonal antibody
CN113874518B (en) 2019-03-18 2025-04-25 生物辐射Abd瑟罗泰克有限公司 Protection of SpyTag-containing periplasmic fusion proteins from degradation by the proteases Tsp and OmpT
CN114829578B (en) * 2019-08-05 2024-09-24 瓦克化学股份公司 Bacterial strains for release of recombinant proteins in fermentation methods

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
US5264365A (en) 1990-11-09 1993-11-23 Board Of Regents, The University Of Texas System Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides
US5508192A (en) 1990-11-09 1996-04-16 Board Of Regents, The University Of Texas System Bacterial host strains for producing proteolytically sensitive polypeptides
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
CA2134550A1 (en) 1992-04-28 1993-11-11 Anders Astrom Human crabp-i and crabp-ii
GB9215540D0 (en) 1992-07-22 1992-09-02 Celltech Ltd Protein expression system
US5304472A (en) 1992-11-20 1994-04-19 Genentech, Inc. Method of controlling polypeptide production in bacterial cells
US5639635A (en) 1994-11-03 1997-06-17 Genentech, Inc. Process for bacterial production of polypeptides
AU2660397A (en) 1996-04-05 1997-10-29 Board Of Regents, The University Of Texas System Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US6083715A (en) 1997-06-09 2000-07-04 Board Of Regents, The University Of Texas System Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
JP2000083670A (en) 1998-09-09 2000-03-28 Hsp Kenkyusho:Kk Dsba/dsbb/dsbc/dsbd-expression plasmid
WO2001001147A1 (en) 1999-06-29 2001-01-04 Siga Technologies, Inc. Assay for degp protease inhibitors
GB0006398D0 (en) 2000-03-16 2000-05-03 Novartis Ag Organic compounds
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
AU8867501A (en) 2000-09-01 2002-03-13 Biogen Inc Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design
WO2002018446A2 (en) 2000-09-01 2002-03-07 Biogen, Inc. Methods of designing and producing compounds having improved binding affinity for cd154 or other trimeric proteins
US7041479B2 (en) 2000-09-06 2006-05-09 The Board Of Trustess Of The Leland Stanford Junior University Enhanced in vitro synthesis of active proteins containing disulfide bonds
JP4309656B2 (en) * 2000-12-14 2009-08-05 ジェネンテック・インコーポレーテッド Prokaryotic antibodies and their uses
NZ526134A (en) * 2000-12-14 2005-07-29 Genentech Inc E. coli strain deficient in degP and prc and having a mutant spr gene and a method for making a polypeptide
TWI327597B (en) 2001-08-01 2010-07-21 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
DE60224291T2 (en) 2001-08-27 2008-12-11 Genentech, Inc., South San Francisco SYSTEM FOR ANTIBODY EXPRESSION AND SYNTHESIS
GB0124317D0 (en) 2001-10-10 2001-11-28 Celltech R&D Ltd Biological products
MXPA04004634A (en) 2001-11-16 2004-08-12 Idec Pharma Corp Polycistronic expression of antibodies.
GB0129105D0 (en) 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
ATE328906T1 (en) 2002-06-28 2006-06-15 Domantis Ltd DUAL-SPECIFIC LIGANDS WITH INCREASED HALF-LIFE
US7608429B2 (en) 2002-10-31 2009-10-27 Genentech, Inc. Methods and compositions for increasing antibody production
ES2374068T3 (en) 2002-12-03 2012-02-13 Ucb Pharma, S.A. TEST TO IDENTIFY ANTIBODY PRODUCTION CELLS.
GB0303337D0 (en) 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
DE602004029252D1 (en) 2003-06-13 2010-11-04 Biogen Idec Inc AGLYCOSYL-ANTI-CD154 (CD40-LIGAND) ANTIBODIES AND THEIR USES
ES2315664T3 (en) 2003-06-30 2009-04-01 Domantis Limited SINGLE-DOMAIN ANTIBODIES (DAB) PEGILATED.
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
CA2533593A1 (en) 2003-07-26 2005-02-10 Biogen Idec Ma Inc. Altered antibodies having improved antigen-binding affinity
US8647625B2 (en) 2004-07-26 2014-02-11 Biogen Idec Ma Inc. Anti-CD154 antibodies
CA2577082A1 (en) * 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
GB0425534D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Process for obtaining antibodies
GB0520169D0 (en) 2005-10-04 2005-11-09 Celltech R&D Ltd Biological products
LT2125894T (en) 2007-03-22 2019-03-25 Biogen Ma Inc. Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof
EP2535349A1 (en) 2007-09-26 2012-12-19 UCB Pharma S.A. Dual specificity antibody fusions
US7662587B1 (en) 2009-03-05 2010-02-16 E. I. Du Pont De Nemours And Company Gene knockout mutations that increase peptide production
BR112012006670B8 (en) 2009-09-24 2022-03-03 Ucb Pharma Sa Recombinant gram-negative bacterial cell, and method for producing a recombinant protein
US8470552B2 (en) 2009-10-12 2013-06-25 Keck Graduate Institute Strategy to reduce lactic acid production and control PH in animal cell culture
ES2636971T3 (en) * 2009-11-05 2017-10-10 F. Hoffmann-La Roche Ag Procedures and composition for secretion of heterogeneous polypeptides
GB201000588D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
GB201000587D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201000591D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201000590D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
GB201001791D0 (en) 2010-02-03 2010-03-24 Ucb Pharma Sa Process for obtaining antibodies
GB201012599D0 (en) 2010-07-27 2010-09-08 Ucb Pharma Sa Process for purifying proteins
KR102023786B1 (en) * 2011-07-13 2019-09-20 유씨비 파마, 에스.에이. Bacterial host strain expressing recombinant dsbc
EP2546267A1 (en) 2011-07-13 2013-01-16 UCB Pharma S.A. Bacterial host strain expressing recombinant DsbC
GB201208367D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Biological product

Also Published As

Publication number Publication date
WO2013007388A1 (en) 2013-01-17
EP2731973B1 (en) 2017-11-15
AU2012283388A1 (en) 2014-01-09
JP7062626B2 (en) 2022-05-17
US20170335003A1 (en) 2017-11-23
HUE035674T2 (en) 2018-05-28
BR112013032871A2 (en) 2017-01-24
SMT201800068T1 (en) 2018-03-08
JP6431370B2 (en) 2018-11-28
ME02957B (en) 2018-07-20
EP2731973A1 (en) 2014-05-21
KR102023786B1 (en) 2019-09-20
NO2731973T3 (en) 2018-04-14
ES2659155T3 (en) 2018-03-14
US9725516B2 (en) 2017-08-08
EA031449B1 (en) 2019-01-31
IL229947B (en) 2019-10-31
JP2018019719A (en) 2018-02-08
CN103649124B (en) 2016-04-13
PL2731973T3 (en) 2018-04-30
BR112013032871B1 (en) 2022-09-27
CN103649124A (en) 2014-03-19
CY1119985T1 (en) 2018-12-12
DK2731973T3 (en) 2018-01-29
KR20140039240A (en) 2014-04-01
EP3339325A1 (en) 2018-06-27
MX2014000302A (en) 2014-02-17
EA201490274A1 (en) 2014-05-30
HK1194393A1 (en) 2014-10-17
AU2012283388B2 (en) 2017-04-20
CA2841824C (en) 2021-07-13
MX348738B (en) 2017-06-27
HRP20180226T1 (en) 2018-03-09
SG10201807560XA (en) 2018-10-30
CA2841824A1 (en) 2013-01-17
JP2014521313A (en) 2014-08-28
JP2020028299A (en) 2020-02-27
US9957328B2 (en) 2018-05-01
RS56926B1 (en) 2018-05-31
PT2731973T (en) 2018-02-22
BR112013032871A8 (en) 2022-08-23
LT2731973T (en) 2018-02-26
US20140141468A1 (en) 2014-05-22
SI2731973T1 (en) 2018-04-30

Similar Documents

Publication Publication Date Title
IN2014DN00202A (en)
IL282226A (en) St2 antigen binding proteins
GB201000588D0 (en) Bacterial host strain
MX342034B (en) Monovalent antigen binding proteins.
MX362456B (en) ANTIBODIES AND VACCINES TO BE USED IN THE TREATMENT OF CANCERES BY ROR1 AND TO INHIBIT THE METASTASIS.
WO2014200910A3 (en) Bioinformatic processes for determination of peptide binding
MX366813B (en) Cd3 binding polypeptides.
MX360368B (en) Modified antibody regions and uses thereof.
NZ717399A (en) Antibodies against csf-1r
MX340683B (en) Anti-vla-4 antibodies.
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
GB201000591D0 (en) Bacterial hoist strain
WO2013173706A3 (en) Huwentoxin-iv variants and methods of use
SG191332A1 (en) Recombinant mycobacterium as a vaccine
NZ731491A (en) Cd83 binding proteins and uses thereof
MX362393B (en) Expression cassette.
SG11201503432SA (en) Monoclonal antibody against muramyl peptides
MX2015004892A (en) Methods and compositions relating to anti-il-21 receptor antibodies.
MX345739B (en) New adjuvant.